Form 4: Becton Dickinson Executive Reports Stock Transactions Under Pre-Arranged 10b5-1 Plan

Becton Dickinson's EVP & President, Medical, Michael David Garrison, reported the exercise of stock appreciation rights and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Michael David Garrison, EVP & President, Medical at Becton Dickinson & Co. (BDX), reported transactions on July 18, 2025.
• Exercised 6,360 Stock Appreciation Rights (SARs) at an exercise price of $147.68 per share, acquiring 6,360 shares of common stock.
• Disposed of 5,175 shares of common stock at $180.29 per share.
• Sold 1,184 shares of common stock at $180.29 per share.
• Sold 1 share of common stock at $181.50 per share.
• All reported transactions were conducted under a Rule 10b5-1 trading plan adopted on August 2, 2024.
• Following these transactions, Michael David Garrison beneficially owns 4,887 shares of Becton Dickinson common stock.

Sentiment

Score: 5

Explanation: A neutral score as Form 4 filings primarily disclose routine insider transactions, which are not inherently positive or negative for the company's operational performance. The transactions were pre-planned under a 10b5-1 plan, which is a standard practice.

Positives

• Transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned disposition rather than a reaction to immediate market conditions, which is a standard corporate governance practice.
• The exercise of Stock Appreciation Rights (SARs) suggests the SARs were in-the-money, allowing the executive to realize value from previously granted equity compensation.

Negatives

• The executive sold a significant number of shares (6,360 shares acquired and 6,360 shares disposed of), reducing their direct beneficial ownership in the company.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports past and planned insider transactions.

Management Comments

• The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2024.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, common across all publicly traded companies. It reflects an executive's personal financial planning rather than a direct reflection of broader industry trends or competitive positioning within the medical technology sector.

Comparison to Industry Standards

• Insider transactions, particularly those executed under Rule 10b5-1 plans, are standard practice for executives in publicly traded companies across all industries, including medical technology. These plans allow executives to sell shares systematically while avoiding accusations of trading on material non-public information.
• The specific volume of shares sold by Michael David Garrison is relative to his overall compensation and equity holdings at Becton Dickinson, a large medical technology company. Without specific data on comparable executive sales at peer companies like Medtronic (MDT), Abbott Laboratories (ABT), or Danaher (DHR) during similar periods, a direct quantitative comparison is not feasible from this filing alone.
• The use of a 10b5-1 plan aligns with best practices for corporate governance in executive share dispositions, demonstrating a pre-planned approach to equity monetization.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be perceived as a slight negative signal, though this is largely mitigated by the use of a Rule 10b5-1 plan, which indicates a pre-planned disposition rather than a reaction to immediate company news. The reduction in direct beneficial ownership by the EVP & President, Medical, might be noted by investors.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions by an executive under a pre-arranged 10b5-1 plan. Such transactions are common for executives managing their personal finances and do not typically reflect a change in the company's fundamental outlook or performance. The filing provides no new information regarding Becton Dickinson's operational results, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on the company's broader fundamentals rather than this specific insider activity.

Keywords

Becton Dickinson, BDX, Form 4, Insider Trading, Stock Appreciation Rights, SARs, Rule 10b5-1, Executive Compensation, Stock Sale